Two recent developments involving the California Institute for Regenerative Medicine (CIRM) again serve to underscore the reality that adult and other non-embryonic avenues of stem cell research are
advancing at a far more
dramatic pace toward providing actual
therapeutic benefits for patients than is human embryonic stem cell research (hESCR).